{"id":"W2599933157","doi":"10.1200/jco.2012.30.15_suppl.4105","title":"Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"","keywords":"Medicine; Sorafenib; XIAP; Hepatocellular carcinoma; Clinical endpoint; Internal medicine; Combination therapy; Gastroenterology; Oncology; Apoptosis; Surgery; Randomized controlled trial; Urology; Caspase; Programmed cell death","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001432691,0.001900051,0.003188191,0.0005281616,0.0003593371,0.0009496767,0.0008580908,0.001375349,0.006888676],"category_scores_gemma":[0.0008393895,0.0008306448,0.001248322,0.0004886418,0.001046496,0.000839956,0.000434451,0.00236878,0.001304822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009016795,"about_ca_system_score_gemma":0.001394868,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009978318,"about_ca_topic_score_gemma":0.002200073,"domain_scores_codex":[0.9995284,0.0002344162,0.00002379469,0.00007914614,0.00003874559,0.0000955049],"domain_scores_gemma":[0.9994138,0.0000955909,0.0001104947,0.00005026805,0.00003474424,0.0002950495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.950489,0.01749524,0.001085465,0.000493382,0.000717219,0.0001001162,0.00008027769,0.000754311,0.00804712,0.0001671706,0.001134843,0.01943588],"study_design_scores_gemma":[0.8556731,0.1407542,0.001453234,0.0000133893,0.0002029098,0.00005824458,0.00001923226,0.0004057017,0.0005802761,0.00009233987,0.0007351624,0.0000120455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880581,0.002297915,0.0008437234,0.0004900862,0.0003941222,0.004679284,0.001161658,0.0001480495,0.001927143],"genre_scores_gemma":[0.9854767,0.001724054,0.001491817,0.0008062928,0.0003654341,0.004518006,0.001467862,0.00002732209,0.004122514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006888676,"threshold_uncertainty_score":0.02304494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03802003544661577,"score_gpt":0.3482368006178546,"score_spread":0.3102167651712389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}